191 related articles for article (PubMed ID: 35187076)
1. A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease.
Hernández González JE; Eberle RJ; Willbold D; Coronado MA
Front Mol Biosci; 2021; 8():816166. PubMed ID: 35187076
[TBL] [Abstract][Full Text] [Related]
2. Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen.
Kuzikov M; Costanzi E; Reinshagen J; Esposito F; Vangeel L; Wolf M; Ellinger B; Claussen C; Geisslinger G; Corona A; Iaconis D; Talarico C; Manelfi C; Cannalire R; Rossetti G; Gossen J; Albani S; Musiani F; Herzog K; Ye Y; Giabbai B; Demitri N; Jochmans D; Jonghe S; Rymenants J; Summa V; Tramontano E; Beccari AR; Leyssen P; Storici P; Neyts J; Gribbon P; Zaliani A
ACS Pharmacol Transl Sci; 2021 Jun; 4(3):1096-1110. PubMed ID: 35287429
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
4. Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development.
Yan S; Wu G
FASEB J; 2021 May; 35(5):e21573. PubMed ID: 33913206
[TBL] [Abstract][Full Text] [Related]
5. Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease.
Eberle RJ; Sevenich M; Gering I; Scharbert L; Strodel B; Lakomek NA; Santur K; Mohrlüder J; Coronado MA; Willbold D
ACS Chem Biol; 2023 Feb; 18(2):315-330. PubMed ID: 36647580
[TBL] [Abstract][Full Text] [Related]
6. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
7. Exploration of chalcones as 3-chymotrypsin-like protease (3CL
Lam TP; Nguyen DN; Mai TT; Tran TD; Le MT; Huynh PNH; Nguyen DT; Tran VH; Trinh DT; Truong P; Vo CT; Thai KM
Struct Chem; 2022; 33(5):1707-1725. PubMed ID: 35811783
[TBL] [Abstract][Full Text] [Related]
8. Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.
Wang H; Wen J; Yang Y; Liu H; Wang S; Ding X; Zhou C; Zhang X
Front Pharmacol; 2022; 13():1036208. PubMed ID: 36467060
[No Abstract] [Full Text] [Related]
9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods.
Singh E; Khan RJ; Jha RK; Amera GM; Jain M; Singh RP; Muthukumaran J; Singh AK
J Genet Eng Biotechnol; 2020 Nov; 18(1):69. PubMed ID: 33141358
[TBL] [Abstract][Full Text] [Related]
11. Prioritisation of Compounds for 3CL
Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U
Molecules; 2021 May; 26(10):. PubMed ID: 34070140
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
13. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel inhibitors for SARS-CoV-2 as therapeutic options using machine learning-based virtual screening, molecular docking and MD simulation.
Samad A; Ajmal A; Mahmood A; Khurshid B; Li P; Jan SM; Rehman AU; He P; Abdalla AN; Umair M; Hu J; Wadood A
Front Mol Biosci; 2023; 10():1060076. PubMed ID: 36959979
[TBL] [Abstract][Full Text] [Related]
15. Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Chu LH; Choy WY; Tsai SN; Rao Z; Ngai SM
Protein Sci; 2006 Apr; 15(4):699-709. PubMed ID: 16600962
[TBL] [Abstract][Full Text] [Related]
16. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
[TBL] [Abstract][Full Text] [Related]
17. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
[TBL] [Abstract][Full Text] [Related]
18. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
19. In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.
Ghufran M; Ullah M; Khan HA; Ghufran S; Ayaz M; Siddiq M; Abbas SQ; Hassan SSU; Bungau S
Bioengineering (Basel); 2023 Jan; 10(1):. PubMed ID: 36671672
[TBL] [Abstract][Full Text] [Related]
20. The dolabellane diterpenes as potential inhibitors of the SARS-CoV-2 main protease: molecular insight of the inhibitory mechanism through computational studies.
Aminah NS; Abdjan MI; Wardana AP; Kristanti AN; Siswanto I; Rakhman KA; Takaya Y
RSC Adv; 2021 Dec; 11(62):39455-39466. PubMed ID: 35492446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
